Elan Dismisses Merger Speculation
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan said it is not in discussions with Biogen Idec concerning a potential merger or business combination of the two companies
You may also be interested in...
Biogen Idec Doubling Multiple Sclerosis Sales Force For Antegren Launch
The company will have almost 200 MS sales reps by the time Antegren is expected to launch in early 2005. Partner Elan also will contribute specialty reps for the hospital outpatient setting. Biogen Idec's pre-launch efforts are focusing on reimbursement and neurologists' capacities for I.V. administration.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.